



Healthscope

Healthscope Limited
ACN 144 840 639
Level 1, 312 St Kilda Road
Melbourne Victoria 3004
Tel: (03) 9926 7500
Fax: (03) 9926 7599
www.healthscope.com.au

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

Healthscope successfully completes bookbuild for its initial public offer

25 July 2014

Healthscope Limited (**Healthscope**), Australia's second largest private hospital operator, successfully completed the institutional bookbuild for its initial public offer yesterday. The Final Price was determined at the conclusion of the bookbuild and is \$2.10 per Share.

Key Offer statistics

Final Price per Share	\$2.10
Number of Shares issued or sold under the Offer ¹	1,073.9 million
Total Offer size	\$2,255.2 million
Total number of Shares on issue at Completion of the Offer	1,732.1 million
Market capitalisation on listing	\$3,637.4 million
Final Price per Share / pro forma FY2015F NPAT per Share	21.9x
Enterprise Value / pro forma FY2015F EBITDA	11.6x
Enterprise Value / pro forma FY2015F EBIT	15.8x

1. Includes 225.4 million of Existing Shares and 848.5 million of New Shares.

Healthscope Chairman, Paula Dwyer, said:

"We are delighted with the response to the Offer to date, and look forward to Monday when Healthscope lists on the Australian Securities Exchange. The Offer's success was driven by strong support from key cornerstone investors, other domestic and offshore institutional investors and significant demand from Australian retail investors.

Healthscope has made significant progress since October 2010, implementing strategies to deliver sustainable growth into the future. A strong platform is in place to support Healthscope as it continues to deliver on operational initiatives and enters an exciting growth phase. Healthscope's strategies are supported by strong and attractive fundamentals including Australia's growing and ageing population.

The future looks very bright for Healthscope, with our Key Management committed to the business and strategies, ensuring that the company's great work continues following the Offer. We are excited about the future of Healthscope, and welcome our new shareholders as we begin the next phase of the journey."

The existing shareholder of Healthscope, CT Healthscope Holdings, L.P., acting through its general partner, CT HSP GP (Dutch) B.V., has elected to retain 38% of Healthscope reflecting their strong support for the company and its prospects. CT Healthscope Holdings, L.P.'s limited partners are entities controlled by funds advised and managed by TPG and The Carlyle Group.

Applicants under the Broker Firm Offer should contact their broker to confirm their allocations. Other Applicants wishing to confirm allocations or who have any further queries regarding the Offer can contact the Healthscope Offer Information Line on 1300 705 291 (toll free within Australia) or +61 3



Healthscope

Healthscope Limited
ACN 144 840 639
Level 1, 312 St Kilda Road
Melbourne Victoria 3004
Tel: (03) 9926 7500
Fax: (03) 9926 7599
www.healthscope.com.au

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

9415 4833 (outside Australia) between 9.00am and 5.00pm (Melbourne time), Monday to Friday. The Healthscope Offer Information Line will close on 1 August 2014.

Healthscope's Shares will trade under the code HSO and are expected to commence trading on the Australian Securities Exchange on Monday, 28 July 2014 at midday on a conditional and deferred settlement basis.

For further enquiries, please contact:

Healthscope Investor Relations

Ph: +61 3 9926 7646



Healthscope

Healthscope Limited
ACN 144 840 639
Level 1, 312 St Kilda Road
Melbourne Victoria 3004
Tel: (03) 9926 7500
Fax: (03) 9926 7599
www.healthscope.com.au

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

Disclaimer

This press release does not constitute an offer of securities in the United States or to any person to whom it would not be lawful outside Australia. The securities referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the **US Securities Act**) or under the securities laws of any state or other jurisdiction of the United States. Any securities described in this press release may not be offered or sold in the United States except in compliance with the registration requirements of the US Securities Act and any other applicable securities laws, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and any other applicable securities laws. This press release must not be distributed or released in the United States, or in any jurisdiction outside of Australia where distribution may be restricted by law.

This release is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this release nor anything in it shall form the basis for or of any contract or commitment whatsoever. This release is not a prospectus and does not contain all of the information which would be required to be disclosed in a prospectus. Any decision to purchase or subscribe for shares in Healthscope must be made solely on the basis of the information in the Prospectus and by following the relevant application process, including completing the relevant Application Form. This release does not purport to summarise all information that an investor should consider when making an investment decision. Information in the Prospectus lodged with ASIC may differ materially in both content and document from the information in this release.

This release contains “forward-looking statements” and comments about future events, including Healthscope’s expectations about the Offer, the performance of its businesses and certain strategic transactions. Such forward-looking statements include forecast financial information about Healthscope, statements about industry and market trends, statements about future hospital developments and the progress of current developments and statements about Healthscope’s strategies and the likely outcomes of those strategies. Forward-looking statements can be identified by the use of forward-looking terminology, including without limitation, the terms “believes”, “estimates”, “anticipates”, “expects”, “predicts”, “outlook”, “guidance”, “plans”, “intends”, “should”, “could”, “may”, “will”, “would” and other similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Such forward-looking statements are not guarantees of future performance and have been provided as a general guide only, and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Healthscope and related parties, that may cause actual results to differ materially from those predicted or implied by any forward-looking statements. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. As such, undue reliance should not be placed on any forward-looking statement. Furthermore, nothing contained in this release nor any information made available to you is, or should be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of Healthscope.